Aldeyra Therapeutics Balance Sheet - Quarterly (NASDAQ:ALDX)

Add to My Stocks
$7.85 $0.2 (2.61%) ALDX stock closing price Sep 18, 2018 (Closing)

A thorough fundamental analysis involves using data from Aldeyra Therapeutics balance sheet, apart from other financial statements, to value the business. How cash on hand has increased or decreased is one of the many indicators used while undertaking the Aldeyra Therapeutics stock analysis, and provides insights into the firm's financial performance. Quarterly results are typically accompanied with the company releasing financial statements. Aldeyra Therapeutics had a long term debt of $1M at the end of 2018 Q2. To understand the debt servicing capacity of the company, one needs to look at Aldeyra Therapeutics operating cash flow and Aldeyra Therapeutics revenue also. Aldeyra Therapeutics debt to equity ratio is .

View and download Aldeyra Therapeutics quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Marketable Securities17.07M17.97M22.92M14.8M11.21M11.9M12.89M14.3M14.94M12.87M
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets1.39M1.66M1.01M1.14M------
Total Current Assets
Property Plant & Equipment----------
Accumulated Depreciation----------
Net Property Plant & Equipment
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets----------
Total Assets
Notes Payable----------
Accounts Payable-1.61M1M-------
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses4.16M1.81M2.23M1.5M1.03M1.52M1.94M1.47M1.08M1.03M
Income Taxes Payable----------
Other Current Liabilities----------
Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt1M1.1M1.22M-1.01M1.12M1.23M--1.1M
Non-Current Capital Leases----------
Other Long-Term Liabilities----------
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus154.05M144.03M139.24M138.57M111.03M110.37M98.93M98.3M97.37M84.08M
Retained Earnings-117.09M-108.03M-99.64M-92.68M-87.7M-82.39M-77.3M-72.64M-67.87M-63.56M
Treasury Stock----------
Other Liabilities--0.01M-0.01M-------
Shareholders Equity36.98M36M39.6M45.9M23.33M27.99M21.64M25.67M29.51M20.52M
Total Liabilities & Shareholders Equity43.29M40.77M44.17M49.22M26.46M31.53M25.18M29.19M32.88M23.43M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The latest Aldeyra Therapeutics stock price, and Aldeyra Therapeutics historical stock prices show the stock price movement over time, and the Aldeyra Therapeutics PE ratio chart displays the PE ratio movement. Apart from stock price, one should also look at balance sheet items which mainly comprise of the following:

  • Assets: ALDX total assets, which was at $43.29M for 2018 Q2 is a balance sheet item representing value of what Aldeyra Therapeutics owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Aldeyra Therapeutics is $6.31M. Shareholders equity comes under liabilities as it is money the company owes the holders of ALDX stock.

Aldeyra Therapeutics Balance Sheet - Key Ratios